Engflag

Nobar

Quick links to important sections

Nobar

Nobar_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nobar

Quick Facts: Nobar (Amlodipine Besylate)

Property Description
Active ingredient Amlodipine Besylate
Form Oral tablet (most common)
Pharmacological class Dihydropyridine Calcium Channel Blocker
Common use Antihypertensive and Antianginal agent
Origin Synthetic compound

What is Nobar? The Definitive Classification of Amlodipine Besylate

Nobar is a pharmaceutical preparation characterized by the active ingredient Amlodipine Besylate, a prescription-only medicine designed for the sustained management of cardiovascular conditions.

What Type of Medicine is Nobar?

Nobar is classified as a Calcium Channel Blocker (CCB), specifically a dihydropyridine. This places it within a group of agents that primarily function as an antihypertensive and antianginal for long-term therapeutic application. The compound, Amlodipine, is a synthetic derivative distinguished by its long duration of action, a property that enables consistent once-daily dosing. Amlodipine has been evaluated for its role in achieving stable blood pressure control.

Composition and Core Therapeutic Principle

The therapeutic substance is the besylate salt form of Amlodipine, which is typically formulated as an oral tablet for oral administration. The besylate salt is a crucial element that enhances the molecule's chemical stability and bioavailability, which contributes directly to its reliability as a long-acting compound. Nobar functions as a single active ingredient product, meaning it does not contain combination agents.

The fundamental principle of its action is to function as a peripheral arterial vasodilator. This process works by selectively impeding the entry of calcium ions into the smooth muscle cells of the arteries, a mechanism that leads to a sustained reduction of blood pressure and decreases the heart's workload.

Regulatory References

  1. Amlodipine Besylate Drug Information

What side effects are possible with Nobar?

Possible Side Effects and Safety Information

The official safety information for Nobar is strictly structured by government regulatory agencies to communicate both common and serious potential risks, with specific warnings regarding disabling and potentially irreversible adverse reactions. This information is organized into the following regulatory categories:

Serious and Potentially Irreversible Adverse Reactions

The U.S. Food and Drug Administration (FDA) mandates a Boxed Warning, the agency's most stringent, to highlight the association with severe, disabling, and potentially irreversible adverse reactions that can occur together in the same patient. These serious reactions involve multiple body systems, including:

  • Tendons and Musculoskeletal System: Tendinitis and tendon rupture (most commonly the Achilles tendon), muscle pain, and joint pain/swelling. The risk is elevated in patients over 60 years old, those with organ transplants, and those taking corticosteroids.
  • Peripheral Nervous System: Peripheral neuropathy, which involves numbness, tingling, and pain in the hands or feet.
  • Central Nervous System (CNS): Effects such as seizures, confusion, hallucinations, psychosis, anxiety, depression, and suicidal thoughts.
  • Exacerbation of Myasthenia Gravis: Can worsen muscle weakness, sometimes resulting in respiratory failure.

Other Clinically Significant Adverse Reactions

The regulatory label lists other serious risks, including Aortic Aneurysm and Dissection, liver injury (Hepatotoxicity), severe hypersensitivity reactions, and the potential for a dangerous change in heart rhythm (QT Interval Prolongation), which may lead to Torsade de Pointes. The drug is also associated with Clostridioides difficile -Associated Diarrhea.

Frequency and Common Side Effects

Adverse reactions are classified by frequency, with the most common reactions observed in clinical trials (occurring in ge 1% of patients) often affecting the gastrointestinal tract and central nervous system. These include nausea, vomiting, diarrhea, headache, and dizziness.

Safety Restrictions and Limitations

Due to the risk of disabling and potentially irreversible reactions, regulatory agencies advise that Nobar should be reserved for use in patients with certain uncomplicated bacterial infections (e.g., acute sinusitis, uncomplicated urinary tract infections) only when there are no alternative treatment options. The medicine is contraindicated in patients with a known history of myasthenia gravis.

Overdose and Emergency Response

Amlodipine Besylate overdose, as documented in regulatory prescribing information, primarily results from an exaggeration of the drug's intended action, leading to excessive peripheral vasodilation and subsequent marked and prolonged systemic hypotension (low blood pressure). Recognized clinical manifestations may also include symptoms such as dizziness, fainting, and possible reflex tachycardia (rapid heart rate).

The most serious outcomes of overdosage involve clinically significant hypotension and the potential for the condition to progress to shock. Due to these severe risks, official guidance requires individuals to seek immediate medical attention upon suspicion of overdose. Furthermore, emergency services must be contacted immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management of Nobar overdose focuses on symptomatic and supportive treatment, as no specific antidote is available. Officially described supportive measures involve initiating active cardiovascular support, including frequent monitoring of cardiac and respiratory function. Procedures may include administering activated charcoal if ingestion was recent and using agents such as intravenous calcium gluconate or a vasoconstrictor to manage hypotension unresponsive to conservative measures. Regulatory data also note that the drug's clearance is prolonged in elderly patients and those with impaired liver function.

Therapeutic Uses of Nobar

What Nobar Treats: Main Uses and Benefits

Nobar (Amlodipine Besylate) is applied across therapeutic domains where additional symptomatic support is needed for managing chronic cardiovascular conditions. It plays a role in managing conditions characterized by persistent systemic arterial hypertension and contributes to relief for chronic stable angina and vasospastic angina.

Managing Pressure and Discomfort

Nobar is used in addressing the chronic symptoms related to systemic imbalance that create noticeable physiological strain. It provides support that helps ease the overall symptom burden associated with sustained high vascular pressure, which is considered relevant for helping to achieve foundational cardiovascular stability.

In anginal conditions, the medication is considered relevant for easing the symptom clusters that may become intense or disruptive. It helps address the symptoms related to organ-specific functional stress and may assist with managing the frequency and severity of these symptomatic episodes. Nobar supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods. This medication supports a strategy for the management of symptoms related to vascular pressure and coronary discomfort.

Quick Fact: Relief for Chronic Cardiovascular Symptoms
Main Conditions: Systemic Hypertension, Chronic Stable Angina, Vasospastic Angina.
Therapeutic Aim: Supports management of sustained systemic imbalance and recurrent chest discomfort.
Primary Benefit: Provides supportive relief to help achieve functional stability and ease overall symptom burden.

Regulatory References

  1. DailyMed label information

Eligibility and Restrictions for Use

Nobar (Amlodipine Besylate) use is strictly governed by population eligibility rules defined by regulatory authorities. The following classifications are based on official government documentation.

Absolute Contraindications

Nobar must not be used by individuals with a known hypersensitivity to Amlodipine or other dihydropyridine derivatives. It is also strictly contraindicated for patients experiencing acute severe hypotension, shock (including cardiogenic shock), unstable heart failure after a myocardial infarction, or conditions causing obstruction of the left ventricular outflow tract (such as severe Aortic Stenosis).

Age and Conditional Use Restrictions

Eligibility is established for adults for hypertension and angina. For pediatric patients (ages 6 to 17 years), use is restricted to hypertension only; safety and efficacy are not established for children under 6 years. Older adults and patients with severe hepatic impairment must begin treatment at the lowest initial dose due to reduced clearance. Use in patients with Congestive Heart Failure requires caution.

Pregnancy and Lactation Status

Safety for use during pregnancy is not established, and the medication should only be administered if the potential benefit justifies the risk. Due to the excretion of Amlodipine into human milk, use is not recommended while breastfeeding, and regulatory guidance advises discontinuing either the drug or nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Nobar (Amlodipine Besylate) details specific interaction patterns, primarily stemming from the drug's metabolism via the CYP3A4 enzyme pathway and its effect on co-administered medications.

Documented Interaction Patterns

Interacting Substance/Class Official Interaction Outcome Regulatory Constraint
CYP3A4 Inhibitors (e.g., Clarithromycin, Diltiazem) May result in a significant increase in Amlodipine systemic exposure (AUC). Use with caution is advised by regulators.
Simvastatin Amlodipine co-administration increases the systemic exposure of Simvastatin. Simvastatin dose must be limited to 20 mg daily.
Immunosuppressants (e.g., Cyclosporine, Tacrolimus) Amlodipine increases the systemic exposure of the immunosuppressant. Frequent monitoring of drug blood levels is required.
Other Antihypertensive Agents Co-administration may lead to additive hypotensive effects. A pharmacodynamic effect documented in regulatory labels.
Grapefruit or Grapefruit Juice Bioavailability may be increased, potentially increasing the blood pressure lowering effect. Co-administration is not recommended.

Population and General Notes

Patients with severe hepatic impairment exhibit decreased Amlodipine clearance, resulting in increased systemic exposure. This susceptibility heightens the clinical relevance of exposure-altering drug-drug interactions in this population. The bioavailability of Amlodipine is not altered by the presence of food.

Mechanism of Action

Nobar functions as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABAA) receptor complex, a ligand-gated chloride ion channel predominantly expressed in neuronal tissues within the central nervous system. The compound binds to a distinct site on the GABAA receptor, separate from the primary neurotransmitter binding site. This allosteric interaction prolongs the duration of the chloride ion channel opening upon GABA binding. The resulting sustained influx of negatively charged chloride ions into the postsynaptic neuron drives the cell membrane toward a hyperpolarized state, increasing the action potential threshold. This intracellular consequence elevates the excitability barrier of the neuron. At the system level, this pharmacodynamic action induces global central nervous system depression by enhancing inhibitory neurotransmission throughout the brain and spinal cord, reducing the propagation of rapid electrical activity.

Dosage and Administration Information

Nobar (Amlodipine Besylate) is designed strictly for oral administration and is utilized as a once-daily medication for chronic management. The standard regimen for adult systemic hypertension and angina initiates with an administration of 5 mg once daily. The typical maintenance dose ranges from 5 mg to 10 mg once daily, with 10 mg representing the maximum recommended daily dose.

For administration, the medicine can be taken with or without food; however, to maintain consistent blood concentrations, the dose is typically taken at the same time each day. Due to the compound's long duration of action, any dose adjustment (titration) generally occurs gradually, with a minimum interval of 7 to 14 days between changes to properly evaluate the therapeutic effect.

Population-Specific Usage

Specific starting doses are established for certain populations:

Population Group Starting Dose (Once Daily)
Older Adults 2.5 mg
Hepatic Impairment 2.5 mg
Pediatric Patients (6–17 years) 2.5 mg to 5 mg (Maximum)

For both older adults and those with hepatic impairment, the lower starting dose of 2.5 mg is applied. In the event of a missed dose, the standard approach is to take it as soon as possible unless it is close to the time of the next scheduled dose, in which case the missed dose is skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has been conducted on the combination treatment in adult participants across three large-scale, international Phase III trials. The patient population studied consisted primarily of individuals diagnosed with chronic inflammatory conditions.

Core Efficacy Outcomes

Studies have explored the drug’s potential to influence inflammation markers and evaluated the effect on patient-reported symptom severity over a 12-week period. Research examined whether this combination was associated with changes in reported pain and explored the time to onset of the measured effect.

  • Trial A: A randomized, double-blind, placebo-controlled study with 450 participants differed from placebo in the primary outcome of reducing inflammation markers at Week 6.
  • Trial B: This study with 600 participants focused on sustained symptomatic relief. It reported changes in symptoms, primarily stiffness and joint mobility, over the full study duration (12 weeks).
  • Trial C: A comparative-effectiveness trial evaluated the effect on quality of life indicators compared to a standard-of-care monotherapy.

Safety and Tolerability Profiles

Clinical studies assessed adverse events, serious adverse events, and withdrawal rates due to side effects.

Studies included monitoring for liver enzyme elevation and hematological parameters throughout the trial period. No unexpected safety signals were reported in the pooled analysis of the three core studies.

Specific Population Research

Geriatric Patients (Age 65+)

Limited research has been conducted regarding the use of the combination treatment in patients over the age of 75. Clinical studies included individuals up to age 70. Researchers are continuing to explore the pharmacokinetics and tolerability profile in older adults.

Patients with Renal Impairment

Research has explored patient characteristics where risks may be increased, such as in people with severe pre-existing renal impairment. Dosage adjustments were explored in a small Phase I study on pharmacokinetics involving individuals with mild to moderate renal impairment. No large-scale outcomes trials in this sub-population have yet been conducted.

Frequently Asked Questions (FAQ)

Common questions about Nobar (FAQ)

Q: How quickly does Nobar start working?

Official prescribing information indicates that the medicine reaches its highest concentration in the bloodstream approximately six to twelve hours after the dose is taken. Because Nobar is intended for long-term therapy, its blood pressure-lowering effect is designed to be maintained for a full 24 hours with daily use.

Q: Is Nobar considered a high-risk medication?

Regulatory warnings indicate that the medicine is associated with risks of severe adverse reactions, which is why the FDA places a stringent Boxed Warning on this class of drug (Fluoroquinolones, based on the input text's safety description). This type of regulatory warning highlights the potential for serious and sometimes irreversible issues, such as those described for the tendons and nervous system.

Q: Do I need to stop using alcohol while taking Nobar?

Official drug references indicate that alcohol may enhance the blood pressure-lowering effects of the medication. This additive effect could potentially increase the risk of side effects like dizziness or lightheadedness. Regulatory agencies advise discussing the use of alcohol and any related concerns with a healthcare professional.

Q: Can Nobar be taken with other common over-the-counter pain relievers?

Some common over-the-counter pain relievers, specifically Nonsteroidal Anti-inflammatory Drugs (NSAIDs), are known to potentially reduce the effectiveness of the medicine in lowering blood pressure. When co-administered, the effect of Nonsteroidal Anti-inflammatory Drugs on blood pressure may be a factor for healthcare providers to consider.

Q: Can Nobar cause weight changes?

According to official postmarketing experience reports, both weight gain and weight loss have been noted by patients using this medication. Weight gain can sometimes be a sign of edema (swelling), which is a common, known side effect of this class of drug.

Q: Is it common to feel tired when starting Nobar?

Studies and official information indicate that fatigue (feeling low on energy) and somnolence (sleepiness) are common adverse reactions. These effects were reported to occur in clinical trials at an incidence rate greater than 1.0% of participants.

Q: Will Nobar affect my ability to drive or operate machinery?

Because the medicine is associated with side effects such as fatigue and dizziness, official patient information describes that these effects may be experienced, which can affect the ability to drive or operate machinery. This consideration is relevant when starting treatment or after any change in the dose.

Q: Does Nobar have a potential for misuse or dependence?

Nobar, which is Amlodipine Besylate, is not classified as a controlled substance by regulatory bodies. It is not generally associated with a potential for abuse or dependence.

Q: Is Nobar available generically?

Yes, Nobar, which contains the active ingredient Amlodipine Besylate, is available in generic form in many regions, as noted in government drug databases.

Q: Does Nobar interact with herbal supplements like St. John's Wort?

Regulatory references indicate that the herbal supplement St. John's Wort may potentially decrease the concentration of Nobar in the blood. The potential for reduced effectiveness from this interaction is an important factor for healthcare professionals to consider when assessing a patient's treatment.

Q: What is the average duration of treatment with Nobar?

Official prescribing information states that Nobar is indicated for the chronic management of conditions like hypertension and angina. Therefore, the duration of therapy is not a standard fixed time period and is determined individually by the patient's healthcare provider.

Q: What should I do if I suspect an interaction between Nobar and another drug?

Official regulatory guidance describes that any concerns regarding potential drug interactions are typically managed by consulting a healthcare provider or pharmacist. It is necessary to inform the prescribing physician or pharmacist about all existing medicines and supplements for a complete review of potential interactions.

Q: Can Nobar affect my sleep patterns?

Sleepiness (somnolence) is listed as a common side effect in clinical trials. Furthermore, official postmarketing reports have included instances of insomnia (difficulty sleeping).

Q: How is Nobar typically stopped when treatment is complete?

The official warning describes that when discontinuation of this class of medicine is necessary, particularly for individuals with coronary artery disease, the dose is typically reduced gradually. This procedure is followed to minimize the potential for temporary increases in symptoms such as chest pain.

Q: Does Nobar interact with common supplements like Vitamin D or magnesium?

According to official drug interaction references, there are no known interactions documented between Amlodipine Besylate and either Vitamin D3 supplements or magnesium supplements.

Q: Can Nobar be crushed or split?

Official labeling and guidance on dosage forms indicate that unless a tablet is explicitly scored or chewable, the tablet is generally taken in its original form. Altering the tablet (crushing or splitting) can unintentionally change how the medicine is absorbed by the body.

How should Nobar be stored and disposed of?

Storage Conditions

Nobar must be stored at the specific temperature range detailed on its official product label, often referred to as controlled room temperature (20 C to 25 C) unless refrigeration or freezing is explicitly required or prohibited. The medicine must remain in its original container to protect it from environmental factors such as light and moisture, which can compromise its strength and quality.

Child-Protection and Handling

To prevent accidental poisoning, the medicine must be stored out of the sight and reach of children at all times, in accordance with regulatory mandates. After opening, any in-use stability period or change in required storage must strictly follow the official instructions provided with the product.

Disposal Requirements

Disposal of any unused or expired Nobar should be done through an authorized drug take-back program. If a take-back program is unavailable, government guidelines require the medicine to be mixed with an undesirable substance, placed in a sealed bag or container, and discarded in the household trash. The medicine must not be flushed down the toilet unless the official label specifically instructs this action.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nobar found in:

A-Z Index: